Archive for the 'Cholesterol' Category
New Blood Test Reveals Risk For Metabolic Syndrome
University of Minnesota researchers have discovered that people with high oxidation levels of the low-density lipoprotein (LDL) particle that carries cholesterol throughout the blood are much more likely to develop metabolic syndrome - which can lead to a considerably increased risk of developing heart disease.Researchers measured oxidized LDL in more than 2,000 generally healthy people aged 33-45 (average age 40) in an ongoing study, called CARDIA.Original post by Allergy News From Medical News Today
No commentsAnalysis: Control Reduces Cardiovascular Risk By 42%
Results of a new analysis of the Treating to New Targets (TNT) study show that intensive low-density lipoprotein (LDL) cholesterol-lowering in patients with stable coronary heart disease (CHD) whose systolic blood pressure was less than 140 mmHg reduced the risk of major cardiovascular events, including heart attack, stroke and resuscitated cardiac arrest, by 42 percent compared with less intensive LDL lowering and uncontrolled blood pressure of 140 mmHg or higher.Led by John B.Original post by Allergy News From Medical News Today
No commentsHigher Cholesterol Increases Risk Of Boichemical Failure After Radical Prostatectomy
Poor cholesterol management may not only affect a man’s risk for prostate cancer, but also his risk of biomedical recurrence after prostatectomy, according to new data from Duke University.Original post by Allergy News From Medical News Today
No commentsTransporting Your Apolipoproteins Testing To The Next Level
Randox produces high quality apolipoprotein tests for the diagnosis, monitoring and research of cardiovascular disease and related conditions. Apolipoproteins are essential components of lipoproteins, for example HDL and LDL, responsible for transporting cholesterol and triglycerides around the body. Six apolipoprotein tests are available from Randox: Apo A-I, Apo A-II, Apo B, Apo C-II, Apo C-III and Apo E.Original post by Allergy News From Medical News Today
No commentsLifeCycle Pharma Announces Positive Data From LCP-AtorFen Phase II Clinical Program
LifeCycle Pharma A/S (OMX:LCP) announced positive results from the company’s Phase II clinical program with LCP-AtorFen, a fixed-dose combination product of atorvastatin and fenofibrate for the treatment of mixed dyslipidemia. LCP-AtorFen is a convenient single tablet with a once-daily dosage profile and is without food effect. “The Phase II clinical program confirmed that LCP-AtorFen was safe and well-tolerated.Original post by Allergy News From Medical News Today
No commentsSorting Of CEA Modulated By Cholesterol, Implications For Inflammatory Bowel Disease
In polarized Caco-2 cells, cholesterol was depleted by a combination of synthesis inhibition and plasma membrane extraction with complexing agents. This led to an increased sorting of CEA to the basolateral surface. Interestingly, polarity was not significantly affected by this approach. The association of CEA to lipid rafts, cholesterol, and sphingolipid-enriched microdomains was inhibited in parallel.This study, performed by a team led by Dr.Original post by Allergy News From Medical News Today
No commentsEffects Of Rimonabant On Cardiometabolic Risk Profile Include Loss Of Visceral Fat And Mobilization Of Liver Fat
At a late breaking presentation made on April 29th during the Annual meeting of the European Atherosclerosis Society held in Istanbul, the investigators of ADAGIO-LIPIDS presented the key findings of a one year trial aiming at further studying the effects of rimonabant on several features of HDL and on a comprehensive set of cardiometabolic markers.Original post by Allergy News From Medical News Today
No commentsMerck Receives Not Approvable Letter From FDA For MK-0524A (ER Niacin/laropiprant)
Merck & Co., Inc. received a Not Approvable action letter from the U.S. Food and Drug Administration (FDA) for the Company’s New Drug Application (NDA) for MK-0524A (ER niacin/laropiprant) for the treatment of primary hypercholesterolemia or mixed dyslipidemia. “We plan to meet with the FDA and to submit additional information to enable the agency to further evaluate the benefit/risk profile of MK-0524A,” said Peter S. Kim, Ph. D.Original post by Allergy News From Medical News Today
No commentsTredaptive Recommended For EU Approval For The Treatment Of Mixed Dyslipidaemia And Primary Hypercholesterolaemia
Merck Sharp & Dohme Limited (MSD) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended marketing approval for ‘Tredaptive’™ (nicotinic acid/laropiprant, MSD) 1000 mg / 20 mg modified-release tablets for the treatment of mixed dyslipidaemia and primary hypercholesterolaemia.Original post by Allergy News From Medical News Today
No commentsTwo Merck Medicines Recommended For Approval In The European Union
Merck & Co., Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended two medicines for marketing approval in the European Union (EU). The CHMP recommended marketing approval for TREDAPTIVE™ (nicotinic acid/ laropiprant, MSD) 1000 mg/20 mg tablets for patients with dyslipidemia or primary hypercholesterolemia. Separately, the U.S.Original post by Allergy News From Medical News Today
No comments